ScholarIQanswers from OpenAlex
Deutsche Schmerzgesellschaft
InstitutionResearch output, impact & collaborations
Deutsche Schmerzgesellschaft is a institution indexed in ScholarIQ from OpenAlex.
What is known about Deutsche Schmerzgesellschaft?
ScholarIQrecord summary
Deutsche Schmerzgesellschaft is a research organisation in Berlin, DE. OpenAlex records 1,130 works and 41,782 citations for it. 330 researchers list it as their most recent affiliation.
How many works does Deutsche Schmerzgesellschaft have?
ScholarIQindexed works
Deutsche Schmerzgesellschaft has 1,130 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Deutsche Schmerzgesellschaft have?
ScholarIQcitation count
Deutsche Schmerzgesellschaft has 41,782 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Deutsche Schmerzgesellschaft?
ScholarIQresearcher count
Deutsche Schmerzgesellschaft has 330 researchers in the ScholarIQ index.
What is the average h-index at Deutsche Schmerzgesellschaft?
ScholarIQavg h-index
Deutsche Schmerzgesellschaft has an average h-index of 56 in OpenAlex.
What is the ROR of Deutsche Schmerzgesellschaft?
ScholarIQror
The ROR for Deutsche Schmerzgesellschaft is on the source record.
What is the OpenAlex record for Deutsche Schmerzgesellschaft?
ScholarIQopenalex
The OpenAlex for Deutsche Schmerzgesellschaft is on the source record.
Who are the most-cited researchers behind Deutsche Schmerzgesellschaft?
ScholarIQtop researchers by citations
What are the most-cited papers on Deutsche Schmerzgesellschaft?
ScholarIQmost cited works
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles, Laurence Albigès, Axel Bex, Éva Compérat, Viktor Grünwald, Ravindran Kanesvaran, H. Kitamura, R. McKay, Camillo Porta, G. Procopio, Manuela Schmidinger, Cristina Suárez, Jeremy Yuen‐Chun Teoh, Guillermo de Velasco, Matthew R. Young, Silke Gillessen
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella, Viktor Grünwald, Paul Nathan, Justin Doan, Homa Dastani, Fiona Taylor, Bryan Bennett, Michael DeRosa, Scott Berry, Kristine Broglio, Elmer Berghorn, Robert J. Motzer
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Żurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean‐Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey A. Sosman, Michael Staehler, Sergio Vázquez Estévez, Burçin Şimşek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler
How much of the research on Deutsche Schmerzgesellschaft is open access?
ScholarIQopen access share
83%OPEN ACCESS